View in EDS

Relationship between brain-derived neurotrophic factor and mild to moderate cognitive impairment in the older Mexican population

Saved in:
Bibliographic Details
Title: Relationship between brain-derived neurotrophic factor and mild to moderate cognitive impairment in the older Mexican population
Authors: E. Rico-Fernández, C.A. Reyes-Hernandez, M.P. Rico-Fernández, F.J. García-Alvarado, H.A. Delgado-Aguirre
Source: Neurology Perspectives, Vol 4, Iss 3, Pp 100158- (2024)
Publisher Information: Elsevier, 2024.
Publication Year: 2024
Collection: LCC:Neurology. Diseases of the nervous system
Subject Terms: Deterioro cognitivo, Factor neurotrófico derivado del cerebro BDNF, Neurology. Diseases of the nervous system, RC346-429
Description: Background: Mild–moderate cognitive impairment is a frequent pathology in the adult population. It is important to explore early expression biomarkers that contribute to early detection and benefit the prognostic outlook. Brain-derived neurotrophic factor (BDNF) is an essential regulator of synaptic plasticity, neuronal survival, and differentiation, and even a critical molecular target for drug development in neurological disorders. It is crucial to carry out studies in the early stages that better clarify the landscape of BDNF. Objective: To compare the serum levels of BDNF in healthy adult patients and those with mild to moderate cognitive impairment. Materials and methods: A casecontrol study in patients over 55- years with cognitive impairment, obtained by the MMSE® and MoCA® screening scales. A total of 191 patients, 102 patients with cognitive impairment (cases) and 89 healthy ones (controls) participated in the study. Blood samples were collected to obtain serum, with the determination of BDNF concentrations. For differences in BDNF concentrations, a one-way analysis of variance was used. The significance level of p
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2667-0496
Relation: http://www.sciencedirect.com/science/article/pii/S2667049624000140; https://doaj.org/toc/2667-0496
DOI: 10.1016/j.neurop.2024.100158
Access URL: https://doaj.org/article/f80fb5d114fc42a4bcce6ebe47ad1a4a
Accession Number: edsdoj.f80fb5d114fc42a4bcce6ebe47ad1a4a
Database: Directory of Open Access Journals
Description
Abstract:Background: Mild–moderate cognitive impairment is a frequent pathology in the adult population. It is important to explore early expression biomarkers that contribute to early detection and benefit the prognostic outlook. Brain-derived neurotrophic factor (BDNF) is an essential regulator of synaptic plasticity, neuronal survival, and differentiation, and even a critical molecular target for drug development in neurological disorders. It is crucial to carry out studies in the early stages that better clarify the landscape of BDNF. Objective: To compare the serum levels of BDNF in healthy adult patients and those with mild to moderate cognitive impairment. Materials and methods: A casecontrol study in patients over 55- years with cognitive impairment, obtained by the MMSE® and MoCA® screening scales. A total of 191 patients, 102 patients with cognitive impairment (cases) and 89 healthy ones (controls) participated in the study. Blood samples were collected to obtain serum, with the determination of BDNF concentrations. For differences in BDNF concentrations, a one-way analysis of variance was used. The significance level of p
ISSN:26670496
DOI:10.1016/j.neurop.2024.100158